Last reviewed · How we verify

Fluticasone 250/salmeterol 25 — Competitive Intelligence Brief

Fluticasone 250/salmeterol 25 (Fluticasone 250/salmeterol 25) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Inhaled corticosteroid/long-acting beta-2 agonist combination. Area: Respiratory.

marketed Inhaled corticosteroid/long-acting beta-2 agonist combination Glucocorticoid receptor (fluticasone); beta-2 adrenergic receptor (salmeterol) Respiratory Small molecule Live · refreshed every 30 min

Target snapshot

Fluticasone 250/salmeterol 25 (Fluticasone 250/salmeterol 25) — Research in Real-Life Ltd. Fluticasone/salmeterol is a combination inhaled corticosteroid and long-acting beta-2 agonist that reduces airway inflammation and dilates airways to improve breathing.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Fluticasone 250/salmeterol 25 TARGET Fluticasone 250/salmeterol 25 Research in Real-Life Ltd marketed Inhaled corticosteroid/long-acting beta-2 agonist combination Glucocorticoid receptor (fluticasone); beta-2 adrenergic receptor (salmeterol)
RELVAR/BREO RELVAR/BREO GlaxoSmithKline marketed Inhaled corticosteroid/long-acting beta-2 agonist combination Glucocorticoid receptor; beta-2 adrenergic receptor
Advair Diskus100/50 µg Advair Diskus100/50 µg University of Florida marketed Inhaled corticosteroid/long-acting beta-2 agonist combination Glucocorticoid receptor (fluticasone); beta-2 adrenergic receptor (salmeterol)
Drug: Budesonide/formoterol (Symbicort Turbuhaler Drug: Budesonide/formoterol (Symbicort Turbuhaler AstraZeneca marketed Inhaled corticosteroid/long-acting beta-2 agonist combination (ICS/LABA) Glucocorticoid receptor (budesonide); beta-2 adrenergic receptor (formoterol)
Budesonide-Formoterol treatment Budesonide-Formoterol treatment AstraZeneca marketed Inhaled corticosteroid/long-acting beta-2 agonist combination (ICS/LABA) Glucocorticoid receptor (budesonide); beta-2 adrenergic receptor (formoterol)
Foster BDP/Formoterol Foster BDP/Formoterol Chiesi Farmaceutici S.p.A. marketed Inhaled corticosteroid/long-acting beta-2 agonist combination (ICS/LABA) Glucocorticoid receptor (beclomethasone); beta-2 adrenergic receptor (formoterol)
Advair HFA MDI 115/21 Advair HFA MDI 115/21 Allergy and Asthma Center of El Paso marketed Inhaled corticosteroid/long-acting beta-2 agonist combination Glucocorticoid receptor (fluticasone); beta-2 adrenergic receptor (salmeterol)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Inhaled corticosteroid/long-acting beta-2 agonist combination class)

  1. GlaxoSmithKline · 14 drugs in this class
  2. Pearl Therapeutics, Inc. · 5 drugs in this class
  3. AstraZeneca · 4 drugs in this class
  4. Research in Real-Life Ltd · 3 drugs in this class
  5. Chiesi Farmaceutici S.p.A. · 2 drugs in this class
  6. Istituto per la Ricerca e l'Innovazione Biomedica · 1 drug in this class
  7. Johns Hopkins University · 1 drug in this class
  8. National Jewish Health · 1 drug in this class
  9. SkyePharma AG · 1 drug in this class
  10. University Medical Center Groningen · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Fluticasone 250/salmeterol 25 — Competitive Intelligence Brief. https://druglandscape.com/ci/fluticasone-250-salmeterol-25. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators: